Pfizer expects to seek vaccine authorization for kids between 2 and 11 this September

Pfizer
(Image credit: Getty Images)

Pfizer's COVID-19 vaccine appears set to be authorized for adolescents between 12 and 15, and the company aims to further expand the vaccine's use this September.

Pfizer during an earnings call on Tuesday said it expects to apply for emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine for children between 2 and 11 in September, CNN reports.

A study to examine the safety and efficacy of the vaccine among those between 6 months and 11 years old is ongoing. Additionally, Pfizer said it's expecting to seek authorization for its vaccine among children between 6 months and 2 years in the fourth quarter of 2021.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

This comes after The New York Times reported on Monday that the Food and Drug Administration is set to authorize Pfizer's vaccine for adolescents between 12 and 15 by early next week, allowing this group to start getting vaccinated before the beginning of the new school year.

Pfizer also announced Tuesday it plans to file for a full FDA approval of its COVID-19 vaccine by the end of the month, which CNBC notes would mean "the company will be able to market the shot directly to consumers."

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us